Business Context and Reporting Period
This Form 8-K Current Report, dated June 1, 2016, covers material events for Lion Biotechnologies, Inc. (Note: The filing metadata references "IOVANCE BIOTHERAPEUTICS, INC.", but the document text explicitly identifies the registrant as Lion Biotechnologies, Inc.). The report details a significant capital raise, executive leadership changes, and board restructuring effective June 1, 2016.
Key Financial Metrics and Capital Structure
- Capital Raise: Entered into a Securities Purchase Agreement for the sale of $100 million in securities.
- Security Composition: The offering consists of 9,684,000 shares of common stock and 11,368,633 shares of newly created Series B Preferred Stock.
- Purchase Price: $4.75 per share for both common and preferred stock.
- Allocation: Approximately 46% of the investment is allocated to common stock and 54% to Series B Preferred Stock.
- Investors: Includes Quogue Capital, OrbiMed Advisors, Frazier Healthcare Partners, Broadfin Capital, and fewer than ten other institutional/accredited investors.
- Expected Closing: On or about June 7, 2016, subject to customary conditions.
Material Changes and Executive Actions
Executive Leadership Changes
- New CEO: Maria Fardis, Ph.D., appointed President and CEO effective June 1, 2016, succeeding Elma Hawkins, Ph.D.
- CEO Compensation: $500,000 annual base salary, $150,000 signing bonus, 500,000 stock options (exercise price $5.87), and 550,000 restricted stock units (RSUs). Target annual incentive is 50% of base salary.
- Outgoing CEO: Elma Hawkins separated amicably. She received a total of $188,462 in accrued salary/vacation/prorated incentive plus a $500,000 severance payment. She will serve as a board adviser for at least three months at $10,000/month.
- CFO Amendment: Molly Henderson's base salary increased to $350,000, with an additional 150,000 stock options and target incentive increased to 40% of base salary.
Board of Directors Restructuring
- Board Size: Increased from five to seven directors.
- New Appointments: Wayne P. Rothbaum appointed Interim Chairman; Dr. Iain Dukes appointed to serve as a director on a future date. Dr. Fardis also joined the board.
- Investor Rights: During the "effective period" (until June 30, 2017 or until Quogue Capital owns less than 5%), the company cannot change board size or amend articles without Quogue's consent. Mr. Rothbaum or Dr. Dukes must serve on the Compensation, Audit, and Nominating committees.
Retention Plan
- Retention bonuses totaling $200,000 each were authorized for Molly Henderson, Michael Lotze, and Steven Fischkoff, payable in installments on December 31, 2016, and June 30, 2017.
Series B Preferred Stock Terms
- Conversion: Convertible to common stock at $4.75 per share pending stockholder approval.
- Dividends: Entitled to dividends on an as-if-converted basis.
- Liquidation: Pari passu with common stock and Series A Preferred Stock.
- Voting: Generally no voting rights, except for matters adverse to their rights or creating senior securities.
Guidance, Risks, and Contingencies
- Closing Risk: There is no assurance the private placement will close as planned on June 7, 2016.
- Registration Rights Penalty: If the company fails to file or have declared effective registration statements within 30 or 90 days respectively, it must pay investors 1% of the aggregate investment for each 30-day period of delay.
- Lock-Up Periods: Officers and directors are restricted from selling shares for 60 days; the company is restricted for 90 days (subject to placement agent consent).
- Stockholder Approval: The conversion feature of the Series B Preferred Stock requires stockholder approval. If not approved, the shares remain non-convertible.
Key Facts for Investor Verification
- Confirm the actual closing date of the $100 million private placement and whether all conditions were met.
- Verify the outcome of the stockholder vote regarding the conversion feature of the Series B Preferred Stock.
- Monitor the filing status of the registration statements for the resale of securities to ensure no penalty payments (1% per 30 days) are triggered.
- Review the impact of the new board composition and the "effective period" restrictions on corporate governance flexibility.
- Assess the financial impact of the new CEO compensation package and retention bonuses on the company's cash burn rate.